Business Context and Reporting Period
This Form 6-K filing covers the month of February 2019 for Anchiano Therapeutics Ltd. (referred to as Chemomab Therapeutics Ltd. in metadata). The filing announces that the Company's initial public offering (IPO) registration statement (File No. 333-229155) was declared effective by the SEC on February 11, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of the IPO.
- Offering Size: 2,652,174 American Depositary Shares (ADSs).
- Share Structure: Each ADS represents five ordinary shares.
- Offering Price: $11.50 per ADS.
- Underwriter: Oppenheimer & Co. Inc. (acting as representative).
Material Changes
The primary material change is the transition to a public company status following the effectiveness of the IPO registration statement. The Company entered into an Underwriting Agreement to issue and sell the ADSs at the stated price, less underwriting discounts and commissions.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It serves as a notification of the IPO effectiveness and includes a press release (Exhibit 99.1) by reference.
Investor Verification Checklist
- Verify the final number of ADSs sold and the total gross proceeds raised in the IPO.
- Confirm the specific underwriting discounts and commissions deducted from the $11.50 per ADS price.
- Review the full Prospectus (File No. 333-229155) for detailed financial statements, risk factors, and use of proceeds.
- Check the attached Press Release (Exhibit 99.1) for additional details on the offering terms.